Clinical studies with mazindol
by
Inoue S.
Division of Geriatric Health and Nutrition,
National Institute of Health and Nutrition,
Tokyo, Japan.
Obes Res 1995 Nov;3 Suppl 4:549S-552S

ABSTRACT

An anoerxiant, mazindol suppresses food intake by 1) stimulating beta-adrenergic receptors, 2) inhibiting the feeding center and, 3) stimulating the satiety center in the hypothalamus. In Japan, mazindol is available for clinical use. We examined the effects of mazindol on 1) body weight, appetite, and abnormalities of obesity-related diseases in long-term use 2) maintenance of the reduced body weight after very-low-calorie diet (VLCD) therapy 3) combined use with VLCD therapy and, 4) inhibition of body weight gain in Prader-Willi syndrome. In long-term effects of mazindol, the average reduction of individual body weight was around 6.8 kg. The appetite of 59% of obese subjects was moderately suppressed. Systolic blood pressure, serum GOT, serum triglyceride, serum cholesterol, and glucose tolerance were also improved. With mazindol, 53.3% of obese subjects kept the reduced body weight after VLCD, in contrast, 20.0% of them kept it without mazindol. Combined use of mazindol with VLCD made the VLCD therapy more effective in outpatients. Two of 3 patients with Prader-Willi syndrome inhibited their body weight gain with mazindol. Thus, mazindol produced positive effects in these studies, although the effects were limited.

Ice
AD/HD
History
Adderall
Serotonin
Pregnancy
Neurotoxicity
VTA/glutamate
Self-medication
Worms on speed
Dopamine uptake
Canine narcolepsy
Appetite suppressants
Methamphetamine FAQ
Methamphetamine psychosis
Methamphetamine/narcolepsy
Amphetamine withdrawal/depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Cannabis.net
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhappiness?
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World